INDEX

Note: Page numbers of article titles are in boldface type.

Abortion, spontaneous, brucellosis and, 135
Abscess, myocardial, transesophageal echocardiography in, 158–159
Adherence, in infective endocarditis, 21–36
Age, as factor in infective endocarditis, 10
Amikacin, in aminoglycoside-resistant enterococcal endocarditis, 120
Aminoglycosides, ceftriaxone and, in infective endocarditis, 105
in native valve endocarditis, 92–93
in prosthetic valve endocarditis, 87–88
in *Staphylococcus aureus* endocarditis, 70–75
Ampicillin, in aminoglycoside-resistant enterococcal endocarditis, 119
Aneurysm, mycotic, infective endocarditis and, 110
Antibiotics, in aminoglycoside-resistant enterococcal endocarditis, 119–120
in brucellar endocarditis, 138–141
in infective endocarditis, pharmacokinetic aspects of diffusion into fibrin vegetations, 38–46
in native valve endocarditis, 92–93
in prosthetic valve endocarditis, 87–88
in Q fever endocarditis, 145–148
in *Staphylococcus aureus* endocarditis, 60–65

Bacteremia(s), nosocomial, infective endocarditis in, 16–17
*Staphylococcus aureus*, distribution of, 54
infective endocarditis due to, 53–68
Bacterial-platelet interactions, in infective endocarditis, 31
Beta-lactams, in aminoglycoside-resistant enterococcal endocarditis, 119, 124–125
resistance traits in, 123
in *Staphylococcus aureus* endocarditis, 60–62
vancomycin and, in aminoglycoside-resistant enterococcal endocarditis, 127–128
Brucella, endocarditis due to, 135–141.
See also *Endocarditis, brucellar*.
pathologic characteristics, 136–137
Brucellosis, geographic distribution, 136
spontaneous abortion due to, 135
Cardiac lesions, and infective endocarditis, 10–11
Cardiac tamponade, echocardiography in, 162
Cardiomyopathy, hypertrophic, and infective endocarditis, 15
Ceftriaxone, aminoglycosides and, in infective endocarditis, streptococcal, 105
in infective endocarditis, 98–107
due to unusual microorganisms, 105–107
staphylococcal, 106–107
streptococcal, 99–105
in humans, 101–105
in vitro activity, 99
*Chlamydia psittaci*, endocarditis due to, 148
Ciprofloxacin, in aminoglycoside-resistant enterococcal endocarditis, 126
combination therapy, 126
in *Staphylococcus aureus* endocarditis, 76–77
Combination therapy, in aminoglycoside-resistant enterococcal endocarditis, 126–128
*Coxiella burnetti*, endocarditis due to, 141–148. See also *Endocarditis, Coxiella burnetti*.
Doxycycline, in Q fever endocarditis, 147
Drug users, infective endocarditis in, 16

Echocardiography, in cardiac tamponade, 162
in congenital heart disease, 161
contrast, 155
Doppler, in infective endocarditis, 154
in heart failure, 159–160
in infective endocarditis, 4–5, 109–110, 153–165
clinical utility of, 161
complications, extracardiac, 163
limitations of, 162–163
technical considerations, 154
in mitral valve perforation, 159
in pericardial effusion, 161–162
in prosthetic valve endocarditis, 160–161
in Staphylococcus aureus endocarditis, 57–60
transesophageal, 155
in myocardial abscess, 158–159
two-dimensional, in valvular vegetations and embolic events, 156–158
types, 154–155
Emboli, infective endocarditis and, 108–109
Endocarditis, brucellar, 135–141
diagnosis, 137–138
pathologic characteristics, 136–137
treatment, 138–141
Chlamydia psittaci, 148
coagulase-negative staphylococci and, 81–96
microbiology of, 82–83
Coxiella burnetii, 141–148
diagnosis, 144–145
pathologic characteristics, 142–143
treatment, 145–148
enterococcal, aminoglycoside-resistant, 117–133
treatment, beta-lactam resistance in, 123
combination therapy, 126–128
gentamicin resistance in, 121–123
glycopeptide resistance in, 124
historical background, 118
monotherapy, 124–126
quinolone resistance in, 124
resistance traits in, 121–124
traditional approaches to, 118–120
infective, bacterial-platelet interactions in, 31
cardiac injury in, 23–25
causes, unusual, 105–107
ceftriaxone in, 98–107. See also Cef-
triaxone, in infective endocarditis.
complications, cardiac surgery for, 155–156
extracardiac, 163
management, 153–165
congenital heart disease and, 161
congestive heart failure in, 107–108
culture-negative, incidence, 2
defined, 22
diagnosis, 1–8
criteria for, 4
echocardiography in, 4–5
Steckelberg criteria for, 3–6
von Reyn criteria for, 2–6
echocardiography in, 109–110, 153–165
clinical utility of, 161
Doppler, 154
limitations of, 162–163
technical considerations, 154
emboli in, 108–109
experimental, animal models of, 71
antibiotics in, 38–46
once-daily dosing requirements, 44
pharmacodynamic factors, treat-
ment, 41–46
pharmacokinetic aspects, treatment, 38–41
incidence, 10, 97
intercellular communication in, ad-
derence events in, 25
issue on, 1–165
mycotic aneurysms in, 110
pathogenesis, 10
adherence events in, 21–36
pathogens of, adherence properties of, 25–27
platelet adherence to cardiac tissues in, 27–30
risk factors for, 9–19
acquired valvular disease, 12
advancing age, 10
cardiac lesions, 10–11
congenital heart disease, 12–13
drug abuse, 16
idiopathic hypertrophic subaortic
stenosis, 15
male gender, 10
Marfan's syndrome, 15
mitral valve prolapse, 13–15
noncardiac disease, 16
nosocomial bacteremias, 16–17
prior endocarditis, 15
procedure-associated, 16–17
prosthetic cardiac valves, 11–12
staphylococcal, ceftriaxone in, 106–
treatment, 97–115
INDEX 169

Heart, injury to, in infective endocarditis, 23–25
Heart disease, congenital, infective endocarditis and, 12–13
echocardiography in, 161
Heart failure, congestive, infective endocarditis and, 107–108
echocardiography in, 159–160

Idiopathic hypertrophic subaortic stenosis, and infective endocarditis, 15

Marfan’s syndrome, and infective endocarditis, 15
Mitral valve perforation, echocardiography in, 159
Mitral valve prolapse, and infective endocarditis, 13–15
Monotherapy, in aminoglycoside-resistant enterococcal endocarditis, 124–126

Nafcillin-aminoglycoside, in Staphylococcus aureus endocarditis, 74
Nafcillin-tobramycin, in Staphylococcus aureus endocarditis, 74

Penicillin, in Staphylococcus aureus endocarditis, 70–75
Penicillin-streptomycin, in aminoglycoside-resistant enterococcal endocarditis, 119–120
Pericardial effusion, echocardiography in, 161–162
Platelets, adherence of, to cardiac tissues, in infective endocarditis, 27–30
Prosthetic valves, and infective endocarditis, 11–12

Q fever, endocarditis due to, 141–148
diagnosis, 144–145
pathologic characteristics, 142–143
treatment, 145–148
Quinolones, in aminoglycoside-resistant enterococcal endocarditis, resistance traits in, 124
in Q fever endocarditis, 147
in Staphylococcus aureus endocarditis, 76–77

Fluoroquinolones, in Staphylococcus aureus endocarditis, 76

Gender, as factor in infective endocarditis, 10

Gentamicin, in aminoglycoside-resistant enterococcal endocarditis, 120
high-level resistance to, 121–123
in brucellar endocarditis, 139
in native valve endocarditis, 92–93

Glycopeptide, in aminoglycoside-resistant enterococcal endocarditis, 125–126
resistance traits in, 124

Fluoroquinolones, in Staphylococcus aureus endocarditis, 76

Heart, injury to, in infective endocarditis, 23–25
Heart disease, congenital, infective endocarditis and, 12–13
echocardiography in, 161
Heart failure, congestive, infective endocarditis and, 107–108
echocardiography in, 159–160

Idiopathic hypertrophic subaortic stenosis, and infective endocarditis, 15

Marfan’s syndrome, and infective endocarditis, 15
Mitral valve perforation, echocardiography in, 159
Mitral valve prolapse, and infective endocarditis, 13–15
Monotherapy, in aminoglycoside-resistant enterococcal endocarditis, 124–126

Nafcillin-aminoglycoside, in Staphylococcus aureus endocarditis, 74
Nafcillin-tobramycin, in Staphylococcus aureus endocarditis, 74

Penicillin, in Staphylococcus aureus endocarditis, 70–75
Penicillin-streptomycin, in aminoglycoside-resistant enterococcal endocarditis, 119–120
Pericardial effusion, echocardiography in, 161–162
Platelets, adherence of, to cardiac tissues, in infective endocarditis, 27–30
Prosthetic valves, and infective endocarditis, 11–12

Q fever, endocarditis due to, 141–148
diagnosis, 144–145
pathologic characteristics, 142–143
treatment, 145–148
Quinolones, in aminoglycoside-resistant enterococcal endocarditis, resistance traits in, 124
in Q fever endocarditis, 147
in Staphylococcus aureus endocarditis, 76–77

Fluoroquinolones, in Staphylococcus aureus endocarditis, 76

Heart, injury to, in infective endocarditis, 23–25
Heart disease, congenital, infective endocarditis and, 12–13
echocardiography in, 161
Heart failure, congestive, infective endocarditis and, 107–108
echocardiography in, 159–160

Idiopathic hypertrophic subaortic stenosis, and infective endocarditis, 15

Marfan’s syndrome, and infective endocarditis, 15
Mitral valve perforation, echocardiography in, 159
Mitral valve prolapse, and infective endocarditis, 13–15
Monotherapy, in aminoglycoside-resistant enterococcal endocarditis, 124–126

Nafcillin-aminoglycoside, in Staphylococcus aureus endocarditis, 74
Nafcillin-tobramycin, in Staphylococcus aureus endocarditis, 74

Penicillin, in Staphylococcus aureus endocarditis, 70–75
Penicillin-streptomycin, in aminoglycoside-resistant enterococcal endocarditis, 119–120
Pericardial effusion, echocardiography in, 161–162
Platelets, adherence of, to cardiac tissues, in infective endocarditis, 27–30
Prosthetic valves, and infective endocarditis, 11–12

Q fever, endocarditis due to, 141–148
diagnosis, 144–145
pathologic characteristics, 142–143
treatment, 145–148
Quinolones, in aminoglycoside-resistant enterococcal endocarditis, resistance traits in, 124
in Q fever endocarditis, 147
in Staphylococcus aureus endocarditis, 76–77
Rifampin, in aminoglycoside-resistant enterococcal endocarditis, combination therapy, 127
in brucellar endocarditis, 139
in native valve endocarditis, 92–93
in prosthetic valve endocarditis, 87–88
in Staphylococcus aureus endocarditis, 77

Staphylococci, antimicrobial susceptibility of, 82–83
coagulase-negative, endocarditis due to, 81–96. See also Endocarditis, coagulase-negative staphylococci and.
described, 82
virulence factors, 82
Staphylococcus aureus, infective endocarditis due to, 53–68. See also Endocarditis, Staphylococcus aureus.
Steckelberg criteria, in infective endocarditis, 3–6
Streptomycin, in aminoglycoside-resistant enterococcal endocarditis, 120
in brucellar endocarditis, 140
Subaortic stenosis, and infective endocarditis, 15

Tetracycline, in brucellar endocarditis, 140
Tobramycin, in Staphylococcus aureus endocarditis, 74
Trimethoprim-sulfamethoxazole (TMP-SMZ), in aminoglycoside-resistant enterococcal endocarditis, 126
in brucellar endocarditis, 139
in Q fever endocarditis, 147

Valvular disease, acquired, and infective endocarditis, 12
Vancomycin, beta-lactams and, in aminoglycoside-resistant enterococcal endocarditis, 127–128
in native valve endocarditis, 92–93
in prosthetic valve endocarditis, 87–88
in Staphylococcus aureus endocarditis, 62–64
Vancomycin-tobramycin, in Staphylococcus aureus endocarditis, 74
Vegetations, valvular, echocardiography in, 156–158
von Reyn criteria, in infective endocarditis, 2–6